THE CURRENT SITUATION OF ADVERSE EVENTS FOLLOWING IMMUNIZATION WITH THE PFIZER COVID-19 VACCINE AMONG WORKERS AT NAM HAI COMPANY, CAN THO IN 2021

Abstract

The study on the Pfizer COVID-1 vaccine was conducted at Nam Hai Company, Can Tho, to address concerns related to adverse events following immunization – AEFI, thereby helping to reduce anxiety and increase understanding of the vaccine's benefits in preventing illness and mortality. This cross-sectional descriptive study was carried out on 150 workers using a systematic sampling method to determine the rate of adverse reactions after the first and second doses of the Pfizer vaccine. The results showed that the incidence of adverse reactions was 70.7% after the first dose and increased to 99.3% after the second dose. Common symptoms included fever, chills, headache, fatigue, and swelling or pain at the injection site, which typically appeared within the first 6 hours and subsided after 48 hours. No severe cases or hospitalizations were recorded. The study concluded that although the rate of adverse events following immunization was relatively high, most symptoms were mild and temporary. This information is useful for developing safe vaccination plans tailored to specific groups within the community.